```html

HIV/AIDS: A Comprehensive Medical Guide

Overview

Human Immunodeficiency Virus (HIV) is a retrovirus that attacks the body’s immune system, specifically CD4+ T‑lymphocytes. If untreated, HIV gradually weakens immune defenses and can progress to Acquired Immunodeficiency Syndrome (AIDS), the most advanced stage of infection.

HIV does not discriminate; it can affect anyone regardless of age, gender, sexual orientation, or socioeconomic status. However, certain populations have higher prevalence due to social, behavioral, and structural factors.

Key Global Statistics (2023)

• Approximately 38.7 million people worldwide are living with HIV (UNAIDS).
• In the United States, about 1.2 million people are living with HIV (CDC).
• New infections have declined by ~30% since 2010, yet over 1.5 million new cases occur each year globally.
• AIDS‑related deaths have fallen from 1.3 million (2005) to 650,000 (2022) due to antiretroviral therapy (ART) expansion.

Symptoms

Symptoms of HIV infection differ depending on the stage of disease.

Acute (Primary) HIV Infection – 2‑4 weeks after exposure

• Fever
• Headache
• Sore throat
• Swollen lymph nodes (neck, armpits, groin)
• Rash (often on trunk)
• Muscle aches
• Joint pain
• Fatigue
• Diarrhea

These symptoms mimic flu or mononucleosis and often resolve within 1‑2 weeks, leading many to miss the diagnosis.

Chronic (Clinical Latency) Phase – months to years

• Persistent generalized lymphadenopathy
• Weight loss (unintentional)
• Recurrent viral or bacterial infections (e.g., oral thrush, herpes zoster)
• Night sweats
• Mild fever
• Skin changes (e.g., seborrheic dermatitis, herpes simplex lesions)

AIDS‑Defining Illnesses (CD4 count <200 cells/mm³)

• Opportunistic infections: Pneumocystis jirovecii pneumonia, Cryptococcal meningitis, Mycobacterium avium complex.
• Specific cancers: Kaposi sarcoma, invasive cervical cancer, non‑Hodgkin lymphoma.
• Neurologic disorders: HIV‑associated dementia, progressive multifocal leukoencephalopathy.
• Severe weight loss (<10% of body weight) – “wasting syndrome”.

Causes and Risk Factors

HIV is transmitted through the exchange of certain bodily fluids that contain the virus.

Primary Modes of Transmission

• Sexual contact (vaginal, anal, or oral) with an infected partner. Unprotected anal sex carries the highest per‑act risk.
• Blood exposure: sharing syringes or other injection equipment, transfusion of contaminated blood (rare in countries with screened blood supplies).
• Mother‑to‑child (vertical) transmission: during pregnancy, labor, delivery, or breastfeeding.

Key Risk Factors

• Having unprotected sex, especially with multiple partners.
• Receptive anal intercourse.
• Injection drug use without sterile equipment.
• Sex work or having a partner who is a sex worker.
• Men who have sex with men (MSM) – higher prevalence in many regions.
• Living in areas with high community prevalence and limited access to testing/treatment.
• Co‑infection with other sexually transmitted infections (STIs) which disrupt mucosal barriers.

Diagnosis

Early detection is essential for initiating treatment and reducing transmission.

Screening Tests

• Fourth‑generation combination immunoassay – detects both HIV antibodies and p24 antigen; can identify infection as early as 2‑4 weeks after exposure.
• Rapid point‑of‑care tests – finger‑stick or oral fluid tests that give results in 20‑30 minutes; useful in community settings.

Confirmatory Testing

• HIV-1/HIV-2 differentiation immunoassay – distinguishes between HIV‑1 and HIV‑2 after a reactive screening test.
• Nucleic Acid Test (NAT) – measures HIV RNA levels; used when acute infection is suspected or when a discrepancy exists.

Baseline Staging

Once infection is confirmed, clinicians assess disease stage:

• CD4+ T‑cell count (cells/mm³) – primary marker of immune health.
• HIV viral load (copies/mL) – indicates how actively the virus is replicating.
• Screening for opportunistic infections (TB, Hepatitis B/C, syphilis, etc.).

Treatment Options

Modern therapy aims to suppress viral replication, preserve immune function, and prevent transmission.

Antiretroviral Therapy (ART)

Current guidelines (WHO, DHHS) recommend a combination of at least three drugs from two different classes for all persons living with HIV, regardless of CD4 count.

• Integrase strand transfer inhibitors (INSTIs) – e.g., dolutegravir, bictegravir (first‑line due to high potency & low side‑effects).
• Non‑nucleoside reverse transcriptase inhibitors (NNRTIs) – e.g., efavirenz, rilpivirine.
• Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) – e.g., tenofovir alafenamide (TAF), emtricitabine.
• Protease inhibitors (PIs) – e.g., darunavir boosted with ritonavir or cobicistat (used when resistance exists).

Most patients take a single *fixed‑dose* tablet once daily, simplifying adherence.

Adjunctive Medications

• Trimethoprim‑sulfamethoxazole prophylaxis for Pneumocystis pneumonia when CD4 <200.
• Cotrimoxazole or azithromycin for Mycobacterium avium complex.
• Vaccinations (influenza, COVID‑19, HPV, hepatitis B) as per immunization guidelines.

Lifestyle & Supportive Measures

• Regular exercise and balanced nutrition to maintain weight and muscle mass.
• Smoking cessation – reduces cardiovascular risk, which is higher in HIV‑positive persons.
• Mental‑health care – screening for depression, anxiety, and substance use disorders.
• Adherence counseling – using pill boxes, smartphone reminders, or directly observed therapy when needed.

Living with HIV/AIDS

With effective ART, many people achieve an undetectable viral load (<200 copies/mL) and live a near‑normal lifespan.

Daily Management Tips

• Take medication exactly as prescribed. Missing doses can lead to resistance.
• Schedule routine lab monitoring: CD4 count and viral load every 3‑6 months.
• Maintain a healthy diet rich in fruits, vegetables, lean proteins, and whole grains.
• Stay physically active – at least 150 minutes of moderate‑intensity aerobic exercise per week.
• Practice safe sex: use condoms and discuss “U=U” (Undetectable = Untransmittable) with partners.
• Inform all health‑care providers of your HIV status to avoid drug interactions.
• Join a support group or connect with peer counselors for emotional support.

Legal & Social Considerations

Many jurisdictions have laws protecting people living with HIV from discrimination in employment, housing, and health care. Familiarize yourself with local statutes and consider counseling if you encounter stigma.

Prevention

Preventing new infections involves a combination of behavioral, biomedical, and structural strategies.

Behavioral Interventions

• Consistent use of condoms during vaginal, anal, and oral sex.
• Limiting number of sexual partners and knowing their HIV status.
• Never sharing needles or injection equipment.

Biomedical Measures

• Pre‑Exposure Prophylaxis (PrEP) – daily oral tenofovir/emtricitabine (Truvada or Descovy) reduces acquisition risk by >90%.
• Post‑Exposure Prophylaxis (PEP) – a 28‑day course of ART started within 72 hours after a potential exposure.
• Male circumcision – decreases heterosexual acquisition risk by ~60%.
• Screening and treating pregnant women with ART greatly reduces mother‑to‑child transmission to <1%.

Structural Approaches

• Increasing access to free or low‑cost testing and treatment.
• Education campaigns that reduce stigma and encourage early testing.
• Harm‑reduction programs (needle‑exchange, supervised injection sites).

Complications if Untreated

Without ART, HIV progressively destroys the immune system, leading to life‑threatening conditions.

• Opportunistic infections – Pneumocystis pneumonia, cryptococcal meningitis, cytomegalovirus retinitis, toxoplasmosis.
• HIV‑associated malignancies – Kaposi sarcoma, invasive cervical cancer, primary CNS lymphoma.
• Neurologic disease – HIV‑associated neurocognitive disorder (HAND), peripheral neuropathy.
• Cardiovascular disease – accelerated atherosclerosis leading to myocardial infarction or stroke.
• Kidney disease – HIV‑associated nephropathy (HIVAN) and chronic kidney disease.
• Liver disease – coinfection with hepatitis B or C increases cirrhosis risk.
• Bone loss – osteopenia/osteoporosis, heightened fracture risk.
• Pregnancy complications – preterm birth, low birth weight if maternal viral load is not suppressed.

When to Seek Emergency Care

---

Sources: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), Mayo Clinic, Cleveland Clinic, UNAIDS, peer‑reviewed journals (Lancet HIV, JAMA). Content reviewed for accuracy as of May 2026.

```